Re-evaluating the first-tier status of fragile X testing in neurodevelopmental disorders
Authors:
- 10 March 2020
- journal article
- research article
- Published by Elsevier in Genetics in Medicine
- Vol. 22 (6) , 1036-1039
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Evaluation of the child with global developmental delay and intellectual disabilityPaediatrics & Child Health, 2018
- Is it time to retire fragile X testing as a first-tier test for developmental delay, intellectual disability, and autism spectrum disorder?Genetics in Medicine, 2017
- Fragile X testing as a second-tier testGenetics in Medicine, 2017
- Do the data really support ordering fragile X testing as a first-tier test without clinical features?Genetics in Medicine, 2017
- Molecular Findings Among Patients Referred for Clinical Whole-Exome SequencingJAMA, 2014
- Comprehensive Evaluation of the Child With Intellectual Disability or Global Developmental DelaysPediatrics, 2014
- Epidemiology of fragile X syndrome: A systematic review and meta‐analysisAmerican Journal of Medical Genetics Part A, 2014
- ACMG Standards and Guidelines for fragile X testing: a revision to the disease-specific supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics and GenomicsGenetics in Medicine, 2013
- Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisionsGenetics in Medicine, 2013
- Fragile X-associated disorders: a clinical overviewJournal of Neurology, 2011